Glenn Stokken, MD
Cardiovascular Disease · Worcester, MANPI 1528354909
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,000 of the $18,851 with a category attached, or 74.3%. Boston Scientific accounts for 97.4% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $11,313, 2.4 times the $4,717 reported in 2019.
Across 37 payments — averaging $509.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$18K
- Baylis Medical Company Inc$352
- Medtronic$145
Across 67 payments — averaging $2158.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$145K
What the payments were for
- Speaking & faculty fees$14,00074%
- Grants$1,2507%
- Travel & lodging$2,34212%
- Food & beverage$8114%
- Education$4492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $18,354 |
| Baylis Medical Company Inc | 1 | $352 |
| Medtronic | 3 | $145 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$11,250
- EMBLEM MRI S-ICD$2,750
- Watchman$2,165
- GENERAL BRADY$1,250
- GENERAL - THERAPIES$451
- NRG needle$352
- SelectSecure$114
How this compares
$18,851 in reported general payments places this provider in the 80th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 407 | $429,415 |
| JardianceEmpagliflozin | 133 | $189,986 |
| XareltoRivaroxaban | 55 | $69,715 |
| EntrestoSacubitril/Valsartan | 15 | $15,833 |
| Dofetilide | 61 | $14,440 |
| Metoprolol Succinate | 425 | $9,654 |
| Flecainide Acetate | 101 | $5,551 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 103 | $2,905 |
| Amiodarone Hcl | 81 | $2,693 |
| Rosuvastatin Calcium | 50 | $2,031 |
| Atorvastatin Calcium | 85 | $1,462 |
| Ezetimibe | 22 | $1,087 |
| Valsartan | 42 | $982 |
| Carvedilol | 90 | $970 |
| SotalolSotalol Hcl | 52 | $909 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Worcester
- Bryon Gentile IiWorcester$235K
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- Kevin CroceChestnut Hill$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.